Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Benefits topic
No spam. Unsubscribe anytime.
Traveris Q2 briefing: St. Charles Parish sees $6.2 million in paid pharmacy claims and a $199,000 guarantee shortfall
Summary
A Traveris presentation to St. Charles Parish school board committees reported roughly 26,000 pharmacy claims in the first half of the plan year and a $199,000 aggregate pricing-guarantee shortfall through quarter two; presenters said specialty drugs account for about 46% of spend and rebates are estimated at about $1.7 million.
Traveris analysts told the St. Charles Parish School Board’s committees that the district’s pharmacy plan recorded just over 26,000 paid claims and about 2,900 unique utilizers in the first six months of the plan year, with total paid pharmacy claims of roughly $6.2 million.
"Through these first 6 months of the plan year, we saw just over 26,000 claims that were filled," said Ashley Almick, Traveris analyst. "And then the total spend for these claims was just over about 6,200,000." She said specialty medications, though a small share of claim volume, are a large share of spend — about 46% of total pharmacy dollars — and that drug-price increases are a principal driver of year-over-year spend growth.
The Traveris team also reported a contract pricing guarantee shortfall through quarter two. "Through quarter 2, we've calculated there to be a total guarantee shortfall or an underperformance on the guarantees by just about a 199,000," Almick said. She explained those guarantees are calculated by category (for example, retail generics) and that some categories’ over-performance can offset others under the contract’s full-offsetting provisions.
Jessie Smith, Traveris customer success manager, framed the presentation and noted timing constraints for the committee: "We're only allotted 20 minutes. Usually, this takes about an hour, so I'm gonna just jump right into it." The report Traveris reviewed covers the plan-year window the presenters gave as 05/01/2025 through 10/31/2025.
On rebates, Traveris calculated minimum rebates of about $1.7 million through quarter two and said rebate-eligible claims represented roughly 6% of claim volume (the firm’s typical book-of-business range is 7–11%). "So we are slightly low," Almick said. She walked committee members through the firm’s method of multiplying eligible claim counts by contract minimum rebate amounts to estimate the rebate floor.
Clinical director Brooke Henry highlighted therapeutic-class drivers: dermatology and specialty agents, GLP-1 antidiabetics (noting large growth in Manjaro utilization), migraine specialty drugs, and oncology agents. Henry said the trend toward biosimilars was visible for certain biologics, reducing branded utilization in some categories.
Board members asked about reporting cadence and historical context. Traveris said the plan receives a quarter‑1, quarter‑2 and a full‑year (quarter‑4) ClearGuard report under the district’s contract; there is no separate quarter‑3 report. The presenters said the quarter‑4/full‑year report will reconcile the aggregate contract guarantees and produce any final reconciliation numbers.
Why it matters: the guarantee shortfall and trends in specialty and GLP‑1 drug spending affect the district’s pharmacy budget and the district’s upcoming procurement planning. Traveris said the firm’s data will help shape a request-for-qualifications for pharmacy benefit manager services when the contract ends next year.
Next steps: the committee moved the broker renewal and related items to the full board for its Wednesday meeting; Traveris agreed to provide follow-up historical variance data and the district said it would distribute the final year report when the quarter‑4 data are available.
